# Gennady Bratslavsky

List of Publications by Year
in descending order



| 174 | 3,847 | 125106 | 169272 |
|---|---|---|---|
| papers | citations | 35 h-index | 56 g-index |

| 177 | 177 | 177 | 5249 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Prostate-specific Antigen Testing in Men with Disabilities: A Cross-sectional Analysis of the Health Information National Trends Survey. European Urology Focus, 2022, 8, 1125-1132. | 1.6 | 1 |
| 2 | Association of Race With Cancer-Related Financial Toxicity. JCO Oncology Practice, 2022, 18, e271-e283. | 1.4 | 23 |
| 3 | ABI1â€based expression signature predicts breast cancer metastasis and survival. Molecular Oncology, 2022, 16, 2632-2657. | 2.1 | 7 |
| 4 | Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).. Journal of Clinical Oncology, 2022, 40, 550-550. | 0.8 | 0 |
| 5 | The association of the use of anxiety and depression medications with PSA testing.. Journal of Clinical Oncology, 2022, 40, 56-56. | 0.8 | 0 |
| 6 | Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2022, 40, 156-156. | 0.8 | 0 |
| 7 | E-cigarette use and the risk of bladder and lung cancer.. Journal of Clinical Oncology, 2022, 40, 443-443. | 0.8 | 5 |
| 8 | Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.. Journal of Clinical Oncology, 2022, 40, 563-563. | 0.8 | 0 |
| 9 | Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss.. Journal of Clinical Oncology, 2022, 40, 164-164. | 0.8 | 0 |
| 10 | Financial toxicity and its effect on screening for prostate and colon cancer.. Journal of Clinical Oncology, 2022, 40, 21-21. | 0.8 | 0 |
| 11 | Correlation of ABI1 and PTEN expression during prostate tumor progression.. Journal of Clinical Oncology, 2022, 40, 172-172. | 0.8 | 0 |
| 12 | Comparison of prostate specific antigen testing in men aged 55 to 69 with and without a history of cancer.. Journal of Clinical Oncology, 2022, 40, 230-230. | 0.8 | 0 |
| 13 | Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with clear cell RCC (ccRCC): Impact of FLCN genomic alteration (GA) status.. Journal of Clinical Oncology, 2022, 40, 292-292. | 0.8 | 0 |
| 14 | Robotic Assisted Caval Replacement for Recurrent Renal Cell Carcinoma Invading the Wall of the Inferior Vena Cava. Urology, 2022, 161, 131-134. | 0.5 | 0 |
| 15 | Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Nature Reviews Urology, 2022, 19, 305-320. | 1.9 | 9 |
| 16 | Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Nonâ€“muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. European Urology, 2022, 81, 223-228. | 0.9 | 8 |
| 17 | Transrectal Ultrasound in Prostate Cancer: Current Utilization, Integration with mpMRI, HIFU and Other Emerging Applications. Cancer Management and Research, 2022, Volume 14, 1209-1228. | 0.9 | 5 |
| 18 | Applications of Focused Ultrasound in the Treatment of Genitourinary Cancers. Cancers, 2022, 14, 1536. | 1.7 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 2022, 28, 831-839. | 3.2 | 12 |
| 20 | What is the impact of ischemic heart disease on PSA testing?. Journal of Clinical Oncology, 2022, 40, e17014-e17014. | 0.8 | 0 |
| 21 | The association of COVID-19 testing with cancer care disruption.. Journal of Clinical Oncology, 2022, 40, e18558-e18558. | 0.8 | 0 |
| 22 | Landscape of fibroblast growth factor receptor (FGFR) genomic alterations (GA) in urothelial bladder cancer (UBC).. Journal of Clinical Oncology, 2022, 40, 4568-4568. | 0.8 | 2 |
| 23 | Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with non-chromophobe RCC (nonchrRCC): Impact of FLCN genomic alteration (GA) status.. Journal of Clinical Oncology, 2022, 40, 4550-4550. | 0.8 | 0 |
| 24 | Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2022, 40, 5063-5063. | 0.8 | 1 |
| 25 | Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UCB) genomic alteration (GA) profile.. Journal of Clinical Oncology, 2022, 40, e16535-e16535. | 0.8 | 0 |
| 26 | A specialized Hsp90 co-chaperone network regulates steroid hormone receptor response to ligand. Cell Reports, 2022, 40, 111039. | 2.9 | 15 |
| 27 | The Role of Heat Shock Protein-90 in the Pathogenesis of Birt-Hogg-DubÃ© and Tuberous Sclerosis Complex Syndromes. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 322-326. | 0.8 | 6 |
| 28 | MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 316-321. | 0.8 | 9 |
| 29 | Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 134.e1-134.e8. | 0.8 | 11 |
| 30 | Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncology, The, 2021, 22, 107-117. | 5.1 | 172 |
| 31 | Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies. European Urology Oncology, 2021, 4, 282-288. | 2.6 | 6 |
| 32 | Genomic landscape of CDK12 mutated metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 165-165. | 0.8 | 2 |
| 33 | HHV-8 positive clinically advanced castrate-resistant prostate cancer (mCRPC): A potentially distinct molecular subset.. Journal of Clinical Oncology, 2021, 39, 163-163. | 0.8 | 0 |
| 34 | Novel synthetic lethality (SL) anti-cancer drug target in urothelial bladder cancer (UCB) based on MTAP genomic loss: Incidence and correlations in standard of care (SOC).. Journal of Clinical Oncology, 2021, 39, 485-485. | 0.8 | 1 |
| 35 | The association between sexual orientation and screening of prevalent gender-specific cancers.. Journal of Clinical Oncology, 2021, 39, 198-198. | 0.8 | 1 |
| 36 | Clinically advanced penile (pSCC) and male urethral (uSCC) squamous cell carcinoma: A comparative genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 2-2. | 0.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Sarcomatoid (srcRCC) versus clear cell (ccRCC) renal cell carcinoma: A comparative comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 349-349. | 0.8 | 2 |
| 38 | Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer. Cancers, 2021, 13, 2426. | 1.7 | 2 |
| 39 | Genomic landscape of MSH6-mutated clinically advanced castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5062-5062. | 0.8 | 1 |
| 40 | Prostate-specific antigen testing in the disabled population: A cross-sectional analysis of the Health Information National Trends Survey (HINTS).. Journal of Clinical Oncology, 2021, 39, e17000-e17000. | 0.8 | 0 |
| 41 | Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 3130-3130. | 0.8 | 1 |
| 42 | The influence of race on financial toxicity among cancer patients.. Journal of Clinical Oncology, 2021, 39, 1525-1525. | 0.8 | 2 |
| 43 | The association of sexual orientation with cancer screening and diagnosis.. Journal of Clinical Oncology, 2021, 39, 6506-6506. | 0.8 | 1 |
| 44 | Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 367.e1-367.e5. | 0.8 | 11 |
| 45 | Abstract 2470: Defining the reciprocal regulation of Abi1 and the androgen receptor in prostate cancer. , 2021, , . | | 0 |
| 46 | Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. Cancers, 2021, 13, 3312. | 1.7 | 9 |
| 47 | Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer, 2021, 127, 3957-3966. | 2.0 | 11 |
| 48 | Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. Cancer, 2021, 127, 4557-4564. | 2.0 | 5 |
| 49 | X-Capsular Incision for Tumor Enucleation (X-CITE)-Technique: A Method to Maximize Renal Parenchymal Preservation for Completely Endophytic Renal Tumors. Urology, 2021, 154, 315-319. | 0.5 | 6 |
| 50 | The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. Nature Structural and Molecular Biology, 2021, 28, 662-670. | 3.6 | 19 |
| 51 | A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 548-560. | 0.8 | 13 |
| 52 | Reoperative Partial Nephrectomyâ€"Does Previous Surgical Footprint Impact Outcomes?. Journal of Urology, 2021, 206, 539-547. | 0.2 | 10 |
| 53 | The association of sexual orientation with prostate, breast, and cervical cancer screening and diagnosis.. Journal of Clinical Oncology, 2021, 39, 129-129. | 0.8 | 0 |
| 54 | Surgical Insights for the Management of Variant Histology in Renal Cell Carcinoma. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 935-942. | 0.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 731.e1-731.e15. | 0.8 | 7 |
| 56 | NF2 Tumor Suppressor Gene Inactivation in Advanced Papillary Renal Cell Carcinoma. American Journal of Surgical Pathology, 2021, 45, 716-718. | 2.1 | 11 |
| 57 | Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. European Urology Focus, 2020, 6, 122-130. | 1.6 | 30 |
| 58 | Liquid buccal mucosa graft endoscopic urethroplasty: a validation animal study. World Journal of Urology, 2020, 38, 2139-2145. | 1.2 | 11 |
| 59 | Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. JAMA Oncology, 2020, 6, 133. | 3.4 | 11 |
| 60 | Fumarate hydratase as a therapeutic target in renal cancer. Expert Opinion on Therapeutic Targets, 2020, 24, 923-936. | 1.5 | 12 |
| 61 | A surgical â€œsewing machineâ€•for rapid graft quilting and suturing in challenging spaces. Urology Video Journal, 2020, 6, 100027. | 0.1 | 1 |
| 62 | Chemical Perturbation of Oncogenic Protein Folding: from the Prediction of Locally Unstable Structures to the Design of Disruptors of Hsp90â€“Client Interactions. Chemistry - A European Journal, 2020, 26, 9459-9465. | 1.7 | 39 |
| 63 | Structural and functional regulation of lactate dehydrogenase-A in cancer. Future Medicinal Chemistry, 2020, 12, 439-455. | 1.1 | 33 |
| 64 | Long-term Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma. Urology, 2020, 140, 85-90. | 0.5 | 15 |
| 65 | Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2327-2336. | 3.2 | 49 |
| 66 | Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. European Urology, 2020, 77, 548-556. | 0.9 | 41 |
| 67 | The emerging target KRAS G12C in genitourinary malignancies.. Journal of Clinical Oncology, 2020, 38, 434-434. | 0.8 | 1 |
| 68 | NF2 mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 726-726. | 0.8 | 6 |
| 69 | Co-chaperones TIMP2 and AHA1 Competitively Regulate Extracellular HSP90:Client MMP2 Activity and Matrix Proteolysis. Cell Reports, 2019, 28, 1894-1906.e6. | 2.9 | 50 |
| 70 | Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. European Urology, 2019, 76, 754-764. | 0.9 | 80 |
| 71 | Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. European Urology Focus, 2019, 5, 748-755. | 1.6 | 29 |
| 72 | Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. Cell Communication and Signaling, 2019, 17, 120. | 2.7 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90. Cell Reports, 2019, 26, 1344-1356.e5. | 2.9 | 38 |
| 74 | Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precision Oncology, 2019, 3, 1-23. | 1.5 | 63 |
| 75 | A comparison of outcomes for standard and multiplex partial nephrectomy in a solitary kidney: The National Cancer Institute experience. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 356.e1-356.e7. | 0.8 | 8 |
| 76 | Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart. Oncologist, 2019, 24, e142-e145. | 1.9 | 22 |
| 77 | Structure and Function of the Nuclear Receptor Superfamily and Current Targeted Therapies of Prostate Cancer. Cancers, 2019, 11, 1852. | 1.7 | 31 |
| 78 | Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 182.e9-182.e15. | 0.8 | 10 |
| 79 | Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx. Targeted Oncology, 2019, 14, 33-38. | 1.7 | 4 |
| 80 | Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. Journal of Urology, 2019, 201, 541-548. | 0.2 | 57 |
| 81 | Penile and uterine cervical squamous cell carcinomas: A comparative genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 514-514. | 0.8 | 2 |
| 82 | Genomic features of metastatic testicular sex cord stromal tumors.. Journal of Clinical Oncology, 2019, 37, 532-532. | 0.8 | 1 |
| 83 | Genomic findings in adenocarcinoma of the urinary bladder.. Journal of Clinical Oncology, 2019, 37, 132-132. | 0.8 | 0 |
| 84 | Malignant pheochromocytoma: A comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 508-508. | 0.8 | 2 |
| 85 | Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling.. Journal of Clinical Oncology, 2019, 37, 280-280. | 0.8 | 0 |
| 86 | Extra-mammary Pagetâ€™s disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2019, 37, 9591-9591. | 0.8 | 1 |
| 87 | Extracellular Phosphorylation of TIMP-2 by Secreted c-Src Tyrosine Kinase Controls MMP-2 Activity. IScience, 2018, 1, 87-96. | 1.9 | 29 |
| 88 | Pathological upstaging of clinical T1 renal cell carcinoma: an analysis of 115,835 patients from National Cancer Data Base, 2004â€“2013. International Urology and Nephrology, 2018, 50, 237-245. | 0.6 | 21 |
| 89 | Identification, Histological Characterization, and Dissection of Mouse Prostate Lobes for In Vitro 3D Spheroid Culture Models. Journal of Visualized Experiments, 2018, , . | 0.2 | 2 |
| 90 | A Festschrift in Honor of Edward M. Messing, MD, FACS. Bladder Cancer, 2018, 4, S1-S43. | 0.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis. American Journal of Surgical Pathology, 2018, 42, 1360-1369. | 2.1 | 27 |
| 92 | PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment.. Journal of Clinical Oncology, 2018, 36, 12091-12091. | 0.8 | 4 |
| 93 | Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT).. Journal of Clinical Oncology, 2018, 36, 4555-4555. | 0.8 | 1 |
| 94 | PBRM1 genomic alterations in mesothelioma: Potential predictor of immunotherapy efficacy.. Journal of Clinical Oncology, 2018, 36, 8562-8562. | 0.8 | 2 |
| 95 | Sporadic renal angiomyolipoma in a patient with Birt-Hogg-DubÃ©: chaperones in pathogenesis. Oncotarget, 2018, 9, 22220-22229. | 0.8 | 11 |
| 96 | Primary urethral carcinoma: A Surveillance, Epidemiology, and End Results data analysis identifying predictors of cancer-specific survival. Urology Annals, 2018, 10, 170. | 0.3 | 36 |
| 97 | Minimally Invasive Radical Nephrectomy Including Vena Cava Thrombus. , 2018, , 63-71. | | 0 |
| 98 | PD-L1 genomic alterations (GA) in solid tumors and hematologic malignancies: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, 12092-12092. | 0.8 | 0 |
| 99 | FGFR3 Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study.. Journal of Clinical Oncology, 2018, 36, 4531-4531. | 0.8 | 0 |
| 100 | Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, e16586-e16586. | 0.8 | 0 |
| 101 | Primary sarcomas of the urinary bladder: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, e16530-e16530. | 0.8 | 0 |
| 102 | Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).. Journal of Clinical Oncology, 2018, 36, 5061-5061. | 0.8 | 0 |
| 103 | The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 153.e15-153.e20. | 0.8 | 39 |
| 104 | Surgical Techniques in the Management of Small Renal Masses. Urologic Clinics of North America, 2017, 44, 233-242. | 0.8 | 7 |
| 105 | Are we underestimating the rates of incontinence after prostate cancer treatment? Results from NHANES. International Urology and Nephrology, 2017, 49, 1715-1721. | 0.6 | 17 |
| 106 | Comparison of survival for partial vs. radical nephrectomy in young patients with T1a renal cell carcinoma treated at commission on cancer-accredited facilities and influence of comorbidities on treatment choice. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 660.e9-660.e15. | 0.8 | 12 |
| 107 | Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer. Cell Reports, 2017, 21, 1883-1895. | 2.9 | 40 |
| 108 | Tumor suppressor Tsc1 is a new Hsp90 coâ€chaperone that facilitates folding of kinase and nonâ€kinase clients. EMBO Journal, 2017, 36, 3650-3665. | 3.5 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Reply to Patrick O. Richard, Micheal A.S. Jewett and Antonio Finelli's Letter to the Editor re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? Eur Urol 2016;70:403â€“6. European Urology, 2017, 71, e47-e48. | 0.9 | 3 |
| 110 | Treatment trends, determinants, and survival of partial and radical nephrectomy for stage I renal cell carcinoma: results from the National Cancer Data Base, 2004â€“2013. International Urology and Nephrology, 2017, 49, 1375-1381. | 0.6 | 10 |
| 111 | Implications of High Rates of Metastatic Prostate Cancer inBRCA2Mutation Carriers. Prostate, 2016, 76, 1135-1145. | 1.2 | 9 |
| 112 | Renal Mass Biopsy: Always, Sometimes, or Never?. European Urology, 2016, 70, 403-406. | 0.9 | 80 |
| 113 | Novel Concept and Method of Endoscopic Urethral Stricture Treatment Using Liquid Buccal Mucosal Graft. Journal of Urology, 2016, 196, 1788-1795. | 0.2 | 13 |
| 114 | An Unusual Etiology of Urinary Retention â€“ Small Cell Prostate Carcinoma. Urology Case Reports, 2016, 7, 53-54. | 0.1 | 1 |
| 115 | Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes. Journal of Endourology, 2016, 30, 1219-1226. | 1.1 | 25 |
| 116 | Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney. International Urology and Nephrology, 2016, 48, 1817-1821. | 0.6 | 18 |
| 117 | The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. Nature Communications, 2016, 7, 12037. | 5.8 | 56 |
| 118 | Pheochromocytoma in Urologic Practice. European Urology Focus, 2016, 1, 231-240. | 1.6 | 7 |
| 119 | Postoperative elevation in creatine kinase and its impact on renal function in patients undergoing complex partial nephrectomy. International Urology and Nephrology, 2016, 48, 1047-1053. | 0.6 | 7 |
| 120 | Chromophobe Renal Cell Carcinoma is the Most Common Nonclear Renal Cell Carcinoma in Young Women: Results from the SEER Database. Journal of Urology, 2016, 195, 847-851. | 0.2 | 14 |
| 121 | Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors. Cell Reports, 2016, 14, 872-884. | 2.9 | 60 |
| 122 | PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study. Abdominal Radiology, 2016, 41, 109-118. | 1.0 | 35 |
| 123 | Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models. Anticancer Research, 2016, 36, 5079-5086. | 0.5 | 16 |
| 124 | The dynamic interactome of human Aha1 upon Y223 phosphorylation. Data in Brief, 2015, 5, 752-755. | 0.5 | 10 |
| 125 | Partial Adrenalectomyâ€”Why Should it be Considered?. Urology Practice, 2015, 2, 359-366. | 0.2 | 3 |
| 126 | Reply. Urology, 2015, 85, 291. | 0.5 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Renal Cell Carcinoma in Young Patients: a Review of Recent Literature. Current Urology Reports, 2015, 16, 1. | 1.0 | 14 |
| 128 | In Obese Patients, the Distance Between Skin and Renal Collecting System Changes with the Position of the Patient from Supine to Prone. Journal of Endourology, 2015, 29, 760-763. | 1.1 | 2 |
| 129 | Robotic-assisted Radical Nephrectomy With Retrohepatic Vena Caval Tumor Thrombectomy (Level III) Combined With Extended Retroperitoneal Lymph Node Dissection. Urology, 2015, 86, 1235-1240. | 0.5 | 28 |
| 130 | c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. Cell Reports, 2015, 12, 1006-1018. | 2.9 | 54 |
| 131 | Preoperative cross-sectional imaging allows for avoidance of unnecessary adrenalectomy during RCC surgery. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 22.e23-22.e27. | 0.8 | 6 |
| 132 | Targeting Hsp90 in urothelial carcinoma. Oncotarget, 2015, 6, 8454-8473. | 0.8 | 31 |
| 133 | Loss of Wave1 gene defines a subtype of lethal prostate cancer. Oncotarget, 2015, 6, 12383-12391. | 0.8 | 9 |
| 134 | Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research. Experimental Biology and Medicine, 2014, 239, 805-812. | 1.1 | 2 |
| 135 | Compared with radical nephrectomy, nephron-sparing surgery offers a long-term survival advantage in patients between the ages of 20 and 44 years with renal cell carcinomas (â‰¤4cm): An analysis of the SEER database. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 549-554. | 0.8 | 22 |
| 136 | Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations. World Journal of Urology, 2014, 32, 623-630. | 1.2 | 13 |
| 137 | Asymmetric Hsp90ÂN Domain SUMOylation Recruits Aha1 and ATP-Competitive Inhibitors. Molecular Cell, 2014, 53, 317-329. | 4.5 | 101 |
| 138 | Molecular mechanisms of tissue inhibitor of metalloproteinase 2 in the tumor microenvironment. Molecular and Cellular Therapies, 2014, 2, 17. | 0.2 | 26 |
| 139 | Abstract B06: Abi1 levels regulate prostate tumor progression in mice downstream from Pten inactivation. , 2014, , . | | 0 |
| 140 | Robot-assisted laparoscopic partial nephrectomy for tumors greater than 4 cm and high nephrometry score: Feasibility, renal functional, and oncological outcomes with minimum 1 year follow-up. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 51-56. | 0.8 | 73 |
| 141 | Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 4584-4584. | 0.8 | 3 |
| 142 | Clinical evaluation of 2-(18F) fluoro-2 deoxy-D-glucose PET/ CT in hereditary leiomyomatosis and renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 383-383. | 0.8 | 3 |
| 143 | Association of partial nephrectomy with a long-term survival advantage in patients between age 20 and 44 with renal cell carcinomas â‰¤ 4 cm: An analysis of the SEER database.. Journal of Clinical Oncology, 2013, 31, 408-408. | 0.8 | 0 |
| 144 | Comparision of histologic distribution of RCC in young and older patients: Results from the SEER database.. Journal of Clinical Oncology, 2013, 31, 419-419. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Decreasing the indications for radical nephrectomy: a study of multifocal renal cell carcinoma. Frontiers in Oncology, 2012, 2, 84. | 1.3 | 12 |
| 146 | Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. Journal of Urology, 2012, 188, 2063-2071. | 0.2 | 211 |
| 147 | Outcomes of Patients with Surgically Treated Bilateral Renal Masses and a Minimum of 10 Years of Followup. Journal of Urology, 2012, 188, 2084-2088. | 0.2 | 40 |
| 148 | A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genetics, 2012, 205, 377-390. | 0.2 | 55 |
| 149 | The Surgical Approach to Multifocal Renal Cancers: Hereditary Syndromes, Ipsilateral Multifocality, and Bilateral Tumors. Urologic Clinics of North America, 2012, 39, 133-148. | 0.8 | 63 |
| 150 | The Impact of Germline BHD Mutation on Histological Concordance and Clinical Treatment of Patients With Bilateral Renal Masses and Known Unilateral Oncocytoma. Journal of Urology, 2011, 185, 2050-2055. | 0.2 | 16 |
| 151 | Feasibility and Outcomes of Partial Nephrectomy for Resection of at Least 20 Tumors in a Single Renal Unit. Journal of Urology, 2011, 185, 49-53. | 0.2 | 26 |
| 152 | Argument in favor of performing partial nephrectomy for tumors greater than 7 cm: The metastatic prescription has already been written. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 829-832. | 0.8 | 7 |
| 153 | Differential Genetic Expression in Large Versus Small Clear Cell Renal Cell Carcinoma: Results from Microarray Analysis. Journal of Cancer, 2011, 2, 271-279. | 1.2 | 4 |
| 154 | Familial Renal Cancer: Molecular Genetics and Surgical Management. International Journal of Surgical Oncology, 2011, 2011, 1-11. | 0.3 | 21 |
| 155 | The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron Levels. Cancer Cell, 2011, 20, 315-327. | 7.7 | 190 |
| 156 | Impact of Genetics on the Diagnosis and Treatment of Renal Cancer. Current Urology Reports, 2011, 12, 47-55. | 1.0 | 20 |
| 157 | Surgical management of large renal tumors. Expert Review of Anticancer Therapy, 2011, 11, 1889-1900. | 1.1 | 2 |
| 158 | Routine adrenalectomy in renal cancerâ€”an antiquated practice. Nature Reviews Urology, 2011, 8, 534-536. | 1.9 | 1 |
| 159 | Management of Locally Recurrent Kidney Cancer. Current Urology Reports, 2010, 11, 15-21. | 1.0 | 11 |
| 160 | Predicting Occult Multifocality of Renal Cell Carcinoma. European Urology, 2010, 58, 118-126. | 0.9 | 26 |
| 161 | UOK 262 cell line, fumarate hydratase deficient (FHâ¯/FHâ¯) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genetics and Cytogenetics, 2010, 196, 45-55. | 1.0 | 131 |
| 162 | The Changing Face of Renal-Cell Carcinoma. Journal of Endourology, 2010, 24, 753-757. | 1.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nature Reviews Urology, 2010, 7, 267-275. | 1.9 | 36 |
| 164 | Oncological Outcomes of Partial Nephrectomy for Multifocal Renal Cell Carcinoma Greater Than 4 cm. Journal of Urology, 2010, 184, 59-63. | 0.2 | 38 |
| 165 | Molecular Diagnosis and Therapy of Kidney Cancer. Annual Review of Medicine, 2010, 61, 329-343. | 5.0 | 154 |
| 166 | Should Preservable Parenchyma, and Not Tumor Size, Be the Main Determinant of the Feasibility of Partial Nephrectomy?. Urology, 2010, 76, 608-609. | 0.5 | 13 |
| 167 | Repeat Partial Nephrectomy on the Solitary Kidney: Surgical, Functional and Oncological Outcomes. Journal of Urology, 2010, 183, 1719-1724. | 0.2 | 62 |
| 168 | Partial Adrenalectomy: Underused First Line Therapy for Small Adrenal Tumors. Journal of Urology, 2010, 184, 18-25. | 0.2 | 85 |
| 169 | The clinical implications of the genetics of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 131-136. | 0.8 | 56 |
| 170 | Partial Nephrectomy After Previous Radio Frequency Ablation: The National Cancer Institute Experience. Journal of Urology, 2009, 182, 2158-2163. | 0.2 | 66 |
| 171 | Initial Experience With Robot Assisted Partial Nephrectomy for Multiple Renal Masses. Journal of Urology, 2009, 182, 1280-1286. | 0.2 | 66 |
| 172 | Feasibility and Outcomes of Repeat Partial Nephrectomy. Journal of Urology, 2008, 180, 89-93. | 0.2 | 94 |
| 173 | Salvage Partial Nephrectomy for Hereditary Renal Cancer: Feasibility and Outcomes. Journal of Urology, 2008, 179, 67-70. | 0.2 | 83 |
| 174 | Pseudohypoxic Pathways in Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 4667-4671. | 3.2 | 76 |